Nuvation Bio (NYSE:NUVB – Get Free Report) and OSR (NASDAQ:OSRH – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.
Institutional and Insider Ownership
61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by company insiders. Comparatively, 36.9% of OSR shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Nuvation Bio and OSR’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nuvation Bio | -88.18% | -46.59% | -22.01% |
| OSR | -593.15% | -8.36% | -6.24% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nuvation Bio | 1 | 2 | 9 | 0 | 2.67 |
| OSR | 1 | 0 | 0 | 0 | 1.00 |
Nuvation Bio currently has a consensus target price of $13.22, indicating a potential upside of 164.18%. Given Nuvation Bio’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Nuvation Bio is more favorable than OSR.
Risk and Volatility
Nuvation Bio has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, OSR has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500.
Earnings & Valuation
This table compares Nuvation Bio and OSR”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nuvation Bio | $62.90 million | 27.94 | -$204.63 million | ($0.44) | -11.38 |
| OSR | $1.81 million | 3.79 | -$27.06 million | ($0.37) | -0.53 |
OSR has lower revenue, but higher earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks.
Summary
Nuvation Bio beats OSR on 8 of the 14 factors compared between the two stocks.
About Nuvation Bio
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
About OSR
OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.
Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.
